首页> 美国卫生研究院文献>Clinical Epidemiology >Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease
【2h】

Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease

机译:系统性硬化症和系统性硬化症相关性间质性肺病的流行病学

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with systemic sclerosis (SSc). To further understand this patient population, we present the first systematic review on the epidemiology of SSc and SSc-associated ILD (SSc-ILD).>Methods: Bibliographic databases and web sources were searched for studies including patients with SSc and SSc-ILD in Europe and North America (United States and Canada). The systematic review was limited to publications in English, German, French, Spanish, Italian, and Portuguese, published between January 1, 2000 and February 29, 2016. For all publications included in the review, the methodologic quality was assessed. For each dimension and region, data availability in terms of quantity and consistency of reported findings was evaluated.>Results: Fifty publications reporting epidemiologic data (prevalence, incidence, demographic profile, and survival and mortality) were included; 39 included patients with SSc and 16 included patients with SSc-ILD. The reported prevalence of SSc was 7.2–33.9 and 13.5–44.3 per 100,000 individuals in Europe and North America, respectively. Annual incidence estimates were 0.6–2.3 and 1.4–5.6 per 100,000 individuals in Europe and North America, respectively. Associated ILD was present in ~35% of the patients in Europe and ~52% of the patients in North America. In Europe, a study estimated the prevalence and annual incidence of SSc-ILD at 1.7–4.2 and 0.1–0.4 per 100,000 individuals, respectively. In both Europe and North America, SSc-ILD was diagnosed at a slightly older age than SSc, with both presentations of the disease affecting 2–3 times more women than men. Ten-year survival in patients with SSc was reported at 65–73% in Europe and 54–82% in North America, with cardiorespiratory manifestations (including ILD) associated with poor prognosis.>Conclusion: This systematic review confirms that SSc and SSc-ILD are rare, with geographic variation in prevalence and incidence.
机译:>背景:间质性肺病(ILD)是系统性硬化症(SSc)患者死亡的主要原因之一。为了进一步了解该患者人群,我们对SSc和与SSc相关的ILD(SSc-ILD)的流行病学进行了首次系统综述。>方法:在书目数据库和网络资源中搜索了包括欧洲和北美(美国和加拿大)的SSc和SSc-ILD。该系统评价仅限于2000年1月1日至2016年2月29日之间以英文,德文,法文,西班牙文,意大利文和葡萄牙文出版的出版物。对于该评价中包括的所有出版物,均对方法学质量进行了评估。对于每个维度和地区,都对报告结果的数量和一致性进行了数据可用性评估。>结果:包括了50种报告流行病学数据(流行率,发病率,人口统计学以及生存和死亡率)的出版物; 39例SSc患者和16例SSc-ILD患者。据报道,在欧洲和北美,SSc的患病率分别为每10万人7.2–33.9和13.5–44.3。在欧洲和北美,每年的发病率估计分别为每10万人0.6-2.3和1.4-5.6。在欧洲,约35%的患者存在相关的ILD,在北美,约52%的患者存在相关ILD。在欧洲,一项研究估计SSc-ILD的患病率和年发病率分别为每100,000个人1.7-4.2和0.1-0.4。在欧洲和北美,SSc-ILD的诊断年龄均比SSc稍大,两种疾病的发病率均比男性高2至3倍。据报道,SSc患者的十年生存率在欧洲为65–73%,在北美为54–82%,并伴有心肺表现(包括ILD)与预后不良相关。>结论:证实SSc和SSc-ILD很少见,患病率和发病率存在地理差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号